MAIA - Gunggung utang perusahaan MAIA Biotechnology, Inc.

R&D developments are creating negative operating leverage, as confirmed by the total debt capital, where the indicator reached the level of 0.00. The financial model of MAIA Biotechnology (MAIA) relies on the future commercialization of therapy for progressive tumors. Investors have access to the first-in-class THIO drug, which is patent-protected and activates immunity by targeting chromosomal ends.

As a biotechnology startup without commercial products, MAIA Biotechnology (MAIA) is critically dependent on external financing to conduct clinical trials. By analyzing the aggregate volume of loans and credits, the debt trajectory allows for an assessment of the real cost of servicing obligations and the risk of insolvency, which determines the fundamental stability of the business in the absence of its own operating income.